Search

Objective: To determine the diagnostic yields of the different types of cell indices alone or in combination with C-reactive-protein(CRP) to distinguish between Pulmonary-tuberculosis(PT) and community-acquired-pneumonia(CAP).Methods: A retrospective cohort study was conducted in a high-complexity care center in Colombia, evaluating different types of cell indices in PT and CAP patients. A-receiver-operating-characteristic (ROC)-curve was plotted, and the area-under ROC-curve was calculated for each of these indices, as well as for CRP and procalcitonin values.Results: A total of 544 subjects were included in the final analysis. Of these, 270(49,6%) were diagnosed with PT and 274(50,4%) with CAP. Patients with CAP had significantly higher levels of leukocytes, neutrophils, monocytes, hemoglobin, hematocrit, and platelets than patients with PT (p < 0,05for-all-comparisons). Procal-citonin did not show significant differences between the groups (p=0,061). CRP has the highest ROC-curve for differentiating between PT and CAP, with ROC-curve of 0,76 (95%CI:0,71-0,88) and 0,75 (95%CI:0,71-0,80), respectively. Procalcitonin did not show discriminatory power for these two diseases, with an ROC-curve of 0,60 (95%CI:0,50-0,71). Conclusion: CRP and blood-cell-markers were the best markers to differentiate between patients with PT and CAP. The performance of these markers was acceptable, suggesting that they could be useful in clinical setting for suspected tuberculosis or CAP.

Objective: To determine relationship between clinical characteristics, laboratory results and treatments with 12 month mortality in COVID-19. Materials and methods: A retrospective cohort study was conducted in three hospitals in Colombia. Odds ratios (OR) were calculated using multivariate logistic regression analysis with outcome variable mortality at 12 months. Results: A total of 1194 patients were included out of 4344 potential eligible subjects, average age was 57.7 years. The group of patients who died at 12 months showed a lymphocyte count of 922.6 (SD:572.32) compared to 1200.1 (SD:749.45) in the group of survivors (p70 years OR:7.2 (95%CI:3.9-13.3) and adjusted OR:1.05 (95%CI:1.01-1.08) (p=0.023), Charlson index >4 OR:7.8 (95%CI:4.3-14.1) and adjusted OR:1.35 (95%CI:1.1-1.67) (p=0.005), dexamethasone OR:0.3 (95%CI:0.2-0.6) and adjusted OR:0.3 (95%CI:0.14-0.65) (p=0.002) and pronation OR:0.3 (95%CI:0.1-1) and adjusted OR:0.4 (95%CI:0.08-1.87) (p=0.242). Conclusions: The increased risk of death 12 months after acute SARS-CoV-2 infection is associated with clinical variables such as age >70 years and Charlson index >4. Use of prone ventilation and dexamethasone were associated with increased survival.